Douglas Cliff/iStock via Getty Images The World Health Organization has issued a warning regarding fake batches of Novo Nordisk's ( NVO ) blockbuster diabetes medication Ozempic (semaglutide) found in the U.S., U.
K., and Brazil. The falsified versions were identified in October 2023 in the U.
K. and Brazil and in December 2023 in the U.S.
The WHO alert noted that the versions made it into the regulated supply chain. The organization warned that the fake batches "can lead to health complications resulting from unmanaged blood glucose levels or weight. In other cases, another undeclared active ingredient may be contained in the injection device, e.
g. insulin, leading to an unpredictable range of health risks or complications." The WHO advises patients to avoid getting drugs from unfamiliar or unverified sources, such as online marketplaces.
More on Novo Nordisk Novo Nordisk: Leading The Fight Against Diabetes And Obesity Novo Nordisk: The Market Is Right, Don't Fight Against It Novo Nordisk: Not The Best Investment Right Now, But A Great Case Study Novo reports new fire at Danish site; third in a month Eli Lilly oral weight-loss candidate orforglipron is potential winner: SA Investing Summit.
